HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Outcome is unchanged by adding vincristine upfront to the Malawi 28-day protocol for endemic Burkitt lymphoma.

AbstractBACKGROUND:
We previously reported a 28-day treatment protocol for children with endemic Burkitt lymphoma (BL) which included four doses of cyclophosphamide (CPM), intrathecal methotrexate and hydrocortisone (IT MTX/HC) at Queen Elizabeth Central Hospital (QECH) in Malawi which resulted in an Event-Free Survival (EFS) of 50% at 1 year.
METHODS:
In an attempt to improve survival whilst maintaining acceptable toxicity, brevity, low-cost and a standard treatment for all patients, four doses of vincristine (VCR) at 1.5 mg/m(2) were added to the backbone of CPM 40 mg/kg on day 1 and 60 mg/kg on days 8,18 and 28 and IT MTX /HC 12.5 mg on days 1,8,18 and 28.
RESULTS:
Seventy cytology confirmed cases of BL, 42 males and 28 females with a median age of 80 years, were treated with this protocol between January 2010 and April 2012. Four percent had St Jude Stage I disease; 29% Stage II; 30% Stage III and 37% Stage IV. Disease site in order of frequency was face (64%); abdomen (47%); CSF (26%) and paraspinal (17%). There were two on-treatment deaths. Sixty-three percent required antibiotics and 19% required blood transfusion. Eighty-one percent of patients achieved complete clinical remission at day 28. Overall predicted EFS at 1 year was 48%; 100% in Stage I, 83% in Stage II, 24% in Stage III and 32% in Stage IV disease. EFS was significantly worse in patients with Stage III/IV disease (P = 0.002) and paraplegia (P = 0.002).
CONCLUSION:
The addition of vincristine to the Malawi 28 day BL treatment protocol did not improve survival.
AuthorsSarita Depani, Kondwani Banda, Simon Bailey, Trijn Israels, George Chagaluka, Elizabeth Molyneux
JournalPediatric blood & cancer (Pediatr Blood Cancer) Vol. 62 Issue 11 Pg. 1929-34 (Nov 2015) ISSN: 1545-5017 [Electronic] United States
PMID26052841 (Publication Type: Clinical Trial, Journal Article)
Copyright© 2015 Wiley Periodicals, Inc.
Chemical References
  • Vincristine
  • Cyclophosphamide
  • Hydrocortisone
  • Methotrexate
Topics
  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
  • Burkitt Lymphoma (drug therapy, epidemiology, mortality)
  • Child
  • Child, Preschool
  • Cyclophosphamide (administration & dosage)
  • Disease-Free Survival
  • Endemic Diseases
  • Female
  • Humans
  • Hydrocortisone (administration & dosage)
  • Malawi (epidemiology)
  • Male
  • Methotrexate (administration & dosage)
  • Neoplasm Staging
  • Survival Rate
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: